What is Infosys?

Infosys to Acquire Life Sciences Consulting and Technology Leader, BASE life science

BENGALURU, India and COPENHAGEN, Denmark, July 13, 2022 /PRNewswire/ -- Infosys (NSE, BSE, NYSE: INFY) a global leader in next-generation digital services and consulting, today announced a definitive agreement to acquire BASE life science, a leading technology and consulting firm in the life sciences industry, in Europe. The acquisition reaffirms our commitment to help global life sciences companies realize business value from cloud-first digital platforms and data, to speed-up clinical trials and scale drug development, positively impacting lives and achieving better health outcomes.

BASE brings to Infosys, domain experts with commercial, medical, digital marketing, clinical, regulatory, and quality knowhow. Backed by a team of data science specialists, BASE is at the frontier of the latest technological developments and trends. It has a strong focus on Data & AI, and the ability to bridge and integrate business logic and technology, driving insights for better health outcomes.

PR Newswire: news distribution, targeting and monitoring

Infosys to Acquire Life Sciences Consulting and Technology Leader, BASE life science

Infosys Logo

NEWS PROVIDED BY

Infosys

13 Jul, 2022, 22:49 IST

Acquisition to deepen life sciences domain capabilities and strengthen footprint across Europe

BASE brings to Infosys, domain experts with commercial, medical, digital marketing, clinical, regulatory, and quality know how. Backed by a team of data science specialists, BASE is at the frontier of the latest technological developments and trends. It has a strong focus on Data & AI, and the ability to bridge and integrate business logic and technology, driving insights for better health outcomes.

Headquartered in Denmark, BASE is one of the fastest growing technology and consulting partners in the life sciences industry. The company has about 200 of the finest, multidisciplinary industry experts across Denmark, Switzerland, UK, Germany, France, Italy, and a nearshore technology hub in Spain. Together with Infosys, BASE will further expand its portfolio of expertise into Consumer Health, Animal Health, MedTech and Genomics segments. BASE collaborates with leading software technology providers in the life sciences industry such as Veeva, IQVIA and Salesforce.

Ravi Kumar S, President, Infosys, said, "This acquisition augments Infosys' deep life sciences expertise, and expands our footprint further in the Nordics region and across Europe, and scales our digital transformation capabilities with cloud-based industry solutions. We are excited to welcome BASE life science and its leadership team into the Infosys family."

"Over the last five years, BASE life science has delivered tremendous growth, and created a stellar life sciences consulting firm in Europe. With Infosys as our catalyst, we will be able to accelerate our expansion internationally and create development opportunities for our people. Infosys is a solid, global technology leader, that is a perfect match for ensuring continuous success of BASE while sharing our common purpose and values.", said Martin Woergaard, CEO, BASE life science.

The acquisition is expected to close during the second quarter of fiscal 2023, subject to customary closing conditions.

VEEVA is a trademark of Veeva Systems Inc.

IQVIA is a trademark of IQVIA Holdings Inc.

Salesforce is a trademark of salesforce.com, inc.

About BASE life science A/S

BASE life science is an innovative and forward-thinking technology, product and service consultancy specialized in creating real business value from digital platforms and data, growing people, and delivering innovative solutions that have a sustainable and lasting impact in an industry that matters.

Its experienced teams optimize technology and business processes within Customer Engagement, Quality, Regulatory, Compliance and Clinical data management for companies within the life science industry

Safe Harbor

Certain statements in this release concerning our future growth prospects, financial expectations and plans for navigating the COVID-19 impact on our employees, clients and stakeholders are forward-looking statements intended to qualify for the 'safe harbor' under the Private Securities Litigation Reform Act of 1995, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding COVID-19 and the effects of government and other measures seeking to contain its spread, risks related to an economic downturn or recession in India, the United States and other countries around the world, changes in political, business, and economic conditions, fluctuations in earnings, fluctuations in foreign exchange rates, our ability to manage growth, intense competition in IT services including those factors which may affect our cost advantage, wage increases in India and the US, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, industry segment concentration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks or system failures, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which Infosys has made strategic investments, withdrawal or expiration of governmental fiscal incentives, political instability and regional conflicts, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property and general economic conditions affecting our industry and the outcome of pending litigation and government investigation. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings, including our Annual Report on Form 20-F for the fiscal year ended March 31, 2022.